Denmark has cut its 2025 economic growth forecast to 1.4% from 3%, citing weaker prospects for pharmaceutical giant Novo ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names Ozempic (pre-filled pen) and ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

Denmark cuts 2025 growth forecast as Novo Nordisk slowdown and US tariffs raise fears of over-reliance on pharma.

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

Replicate Bioscience will partner with Novo Nordisk to develop treatments using self-replicating RNA technology for obesity, type 2 diabetes and other cardiometabolic diseases, the privately held ...

Denmark has cut its 2025 economic growth forecast to 1.4% from 3%, citing weaker prospects for pharmaceutical giant Novo Nordisk and tariffs on Danish goods exported to the US, the country's economy ...

Investing.com -- Novo Nordisk A/S has canceled contracts for new recruits just days or weeks before their start dates as part of broader cost-cutting measures, Bloomberg reports.